[{"NetIncomeLoss_1_Q3_USD":-14255408.0,"UnrecognizedTaxBenefits_0_Q3_USD":0.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":21320000.0,"RepaymentsOfRelatedPartyDebt_3_Q3_USD":0.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q3_USD":276028675.0,"AssetsCurrent_0_Q3_USD":344760.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q3_USD":2760072.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":176006.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_3_Q3_USD":0.0,"CommitmentsAndContingencies_0_Q3_USD":null,"GeneralAndAdministrativeExpense_1_Q3_USD":1113342.0,"GeneralAndAdministrativeExpense_3_Q3_USD":1518286.0,"SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_0_Q3_USD":32386148.0,"Assets_0_Q3_USD":276523435.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"Liabilities_0_Q3_USD":44806220.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":304944.0,"FairValueAdjustmentOfWarrants_1_Q3_USD":13174144.0,"FairValueAdjustmentOfWarrants_3_Q3_USD":2284340.0,"TemporaryEquityAccretionToRedemptionValueAdjustment_1_Q3_USD":-17922.0,"PaymentsOfStockIssuanceCosts_3_Q3_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":0.0,"AssetsHeldInTrustNoncurrent_0_Q3_USD":276178675.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0_Q3_USD":0.0,"IncomeTaxExpenseBenefit_1_Q3_USD":0.0,"IncomeTaxExpenseBenefit_3_Q3_USD":0.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":1129240.0,"ProceedsFromRelatedPartyDebt_3_Q3_USD":0.0,"PrepaidExpenseCurrent_0_Q3_USD":39816.0,"UnrealizedGainLossOnInvestments_3_Q3_USD":2231.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"NetIncomeLoss_3_Q3_USD":-3657398.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"CashEquivalentsAtCarryingValue_0_Q3_USD":0.0,"AdditionalPaidInCapital_0_Q3_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":304944.0,"NonoperatingIncomeExpense_1_Q3_USD":-13142066.0,"NonoperatingIncomeExpense_3_Q3_USD":-2139112.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-362889.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-14255408.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-3657398.0,"TemporaryEquityAccretionToRedemptionValue_3_Q3_USD":4772.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":-186883.0,"UnrealizedGainLossOnInvestments_1_Q3_USD":-106039.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-44312150.0,"ProfitLoss_3_Q3_USD":-3657398.0,"CashFDICInsuredAmount_0_Q3_USD":250000.0,"ProceedsFromIssuanceOfWarrants_3_Q3_USD":0.0,"PreferredStockSharesAuthorized_0_Q3_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":276523435.0,"DeferredIncomeTaxExpenseBenefit_3_Q3_USD":0.0,"PreferredStockValue_0_Q3_USD":0.0,"InvestmentIncomeInterest_1_Q3_USD":138117.0,"InvestmentIncomeInterest_3_Q3_USD":142997.0,"OperatingIncomeLoss_1_Q3_USD":-1113342.0,"OperatingIncomeLoss_3_Q3_USD":-1518286.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":0.0,"StockholdersEquity_0_Q3_USD":-44311460.0,"IncreaseDecreaseInPrepaidExpense_3_Q3_USD":-26157.0,"Ticker":"GLS","CIK":"1805087","name":"CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.","OfficialName":"Gelesis Holdings Inc. Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"341682749.0","Country":"nan","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NYSE","SP500":"nan","filed":"20211116"}]